As such, they are not suited for integration in the clinical management of patients suffering from progressing cancer, in whom a variant of unknown significance (VUS) in a homologous recombination gene, such as BRCA1 or BRCA2, is discovered. The gene discussed is BRCA1; the disease is cancer.